Clinical trials: Histological Response
Head and Neck Cancer
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
Primary Compare response rates (relative change in tumor size) to induction chemotherapy consisting of cisplatin/paclitaxel/cetuximab +/- everolimus.
- Trial name
- NCT01133678
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Carcinoma, Non-Small-Cell Lung
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer
Src expression has been identified in a majority of Non-Small Cell Lung Cancer (NSCLC) cell lines and there is preclinical evidence that Src family kinases may be important in hypoxic growth and angiogenesis in NSCLC.
- Trial name
- TOP0706 (NCT00564876)
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Duke University
Mantle Cell Lymphoma
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
This single arm study will evaluate the benefit of adding MabThera to standard induction chemotherapy in patients with newly diagnosed mantle cell lymphoma.
- Trial name
- NCT00472420
- Testing
- rituximab [MabThera/Rituxan], First line chemotherapy
- Where
- 7 sites in Hungary
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Squamous Cell Carcinoma
An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.
The aim of this study is to compare treatment responses and toxicities of concurrent chemo-radiation with weekly and three weekly Cisplatin in locally advanced Head \& Neck Cancer.
- Trial name
- HNC (NCT03998696)
- Testing
- Cisplatin 40 mg/m2, Cisplatin 100 mg/m2
- Where
- Bangladesh
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial studies the effect of lenalidomide and vaccine in treating patients with early-stage asymptomatic chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene
- Trial name
- NCT01351896
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Skin Cancer, Metastatic Melanoma
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
Background: This study uses a new experimental procedure for treating melanoma that uses the patient's own lymphocytes (type of white blood cell), which are specially selected to target and destroy their tumor.
- Trial name
- NCT00665470
- Testing
- Aldesleukin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
- Trial name
- NCT00623766
- Testing
- Ipilimumab, Corticosteroid: Betamethasone, Corticosteroid: Dexamethasone
- Where
- 14 sites in United States
- Volunteers
- 99 people
- Sponsor
- Bristol-Myers Squibb
Follicular Lymphoma
Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to determine the rate and duration of complete remission and molecular response in patients with relapsed/refractory follicular lymphoma, using a combined treatment with rituximab plus chemotherapy…
- Trial name
- NCT00366275
- Testing
- Immunochemotherapy, in vivo purging and autrotransplant
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Plasma Cell Disorder
Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias
This is a research study to determine if the study drug lenalidomide will increase the body's immune response, which is the body's response against infections or tumors, to hepatitis B vaccine in patients with plasma cell…
- Trial name
- NCT02041325
- Testing
- Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Boston VA Research Institute, Inc.
Multiple Myeloma, AL Amyloidosis
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with…
- Conditions
- Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
- Trial name
- NCT05028374
- Testing
- A single "booster" dose of the Moderna mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to compare how well 2 different dosing schedules of decitabine may help control AML.
- Trial name
- NCT01786343
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients.
- Conditions
- Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
- Trial name
- NCT00901225
- Testing
- G-CSF plus Plerixafor
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Metastatic Cancer, Metastatic Melanoma
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients metastatic cancer that involves taking white blood cells from the patient, growing them in the laboratory…
- Conditions
- Metastatic Cancer, Metastatic Melanoma, Renal Cancer
- Trial name
- NCT01218867
- Testing
- Anti-VEGFR2 CAR CD8 plus PBL, Cyclophosphamide, Aldesleukin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
This phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian…
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Ovarian Brenner Tumor
- Trial name
- NCT01167712
- Testing
- Bevacizumab, Carboplatin, Computed Tomography
- Where
- 564 sites in United States, Canada and 1 more
- Volunteers
- 692 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer
This phase II trial studies how well perflutren protein-type A microspheres and contrast-enhanced ultrasound work in improving response to radioembolization therapy in patients with liver cancer.
- Trial name
- NCT03199274
- Testing
- Yttrium-90 Microsphere Radioembolization, Perflutren Protein-Type A Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Thomas Jefferson University
Sarcoma
Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
The purpose of this study is to determine the overall best tumor response rate to dacarbazine given until disease progression as assessed by RECIST criteria, CT and clinical exams in patients with metastatic sarcomas.
- Trial name
- NCT00802880
- Testing
- Dacarbazine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Washington University School of Medicine
Sarcoma
PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas
Purpose: To assess the utility of PET/MR in assessing response to neoadjuvant radiation therapy in the treatment of high grade sarcomas.
- Trial name
- NCT03076333
- Testing
- PET/MR
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hodgkin Disease, Non-Hodgkin Lymphoma
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
This study investigates whether the prophylactic use of moxifloxacin during high-dose chemotherapy followed by autologous stem cell transplantation reduces the incidence of clinically significant bacteremia.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Multiple Myeloma, Bacteremia
- Trial name
- MoxiProph (NCT00398411)
- Testing
- moxifloxacin
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- University of Cologne
Locally Advanced Solid Tumor, Metastatic Cancer
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT03881488
- Testing
- CTX-471, Pembrolizumab (KEYTRUDA®)
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Compass Therapeutics